Our lead product

MED3000 is a topically applied gel which utilises our proprietary DermaSys®technology, developed specifically for treatment of ED. MED3000 has the potential to be a highly differentiated product by addressing significant unmet needs in the ED market.

Click on the circle icons to view more information about each section.

Speed of action

Data from the FM57 Phase 3 study, and confirmatory FM71 study demonstrated that MED3000 helps men get an erection within 10 minutes. In contrast, 'on demand' oral treatments typically take 30 -60 minutes to act.

Enables spontaneity

Because MED3000 is a fast-acting topical treatment 1, it has the potential to remove the need for planning of sex associated with oral PDE5i medications.

Supports intimacy

As evidenced in the FM57 Phase 3 study 1, and confirmatory FM71 study MED3000’s topical application and speed of erection onset means it can form part of foreplay and support intimate sexual experience.

Safety profile

MED3000 was shown to be an effective treatment for ED in both the FM57 and FM71 Phase 3 studies and demonstrated a highly statistically significant improvement across all ED patient severities than before treatment along with an excellent safety profile. In addition, adverse events were substantially lower than typically seen with oral ED treatments.

The efficacy of Eroxon® is remarkable and has been shown to deliver clinically meaningful benefits to most sufferers with erectile dysfunction in two Phase 3 studies  but with significantly lower adverse events than current first line therapy. With topical application, it will be of particular appeal to mild to moderate ED patients who want a fast onset of action. Lack of drug interactions with prescription products will enable the product to be used with other medications such as nitrates and other cardiovascular drugs.  As such the product will be of great interest to the medical community

Professor David Ralph

Consultant Urologist at University College London and past president of the European Society of Sexual Medicine

  1. FM57 internal clinical study report